

Product Data Sheet

Product Name: Seladelpar sodium salt

Cat. No.: GC37622

Chemical Properties

Cas. No. 3026272-26-1

SMILES O=C([O-])COC1=CC=C(SC[C@H](OCC)COC2=CC=C(C(F)(F)F)C=C2)C=C1C.[Na+]


Formula $C_{21}H_{22}F_3NaO_5S$ M.Wt 466.45

Solubility DMSO: 50 mg/mL (107.19 mM) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Cell experiment: Human PPAR δ , PPAR α and PPAR γ activity is monitored in transiently transfected cells treated with increasing concentrations of MBX-8025 (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM) in comparison with reference compounds (0.1 nM-1 μ M) for individual subtypes. The PPAR subtype selectivity of MBX-8025 is evaluated in a cell-based GAL4 reporter assay system[3].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal experiment: Mouse: From weaning (week 4), Alms1 mutant (foz/foz) NOD.B10 mice or Wt littermates (female mice in both groups) are fed an atherogenic diet (23% fat, 0.2% cholesterol and 45% simple carbohydrate; 4.78 kcal/g digestible energy) ad libitum for 16 weeks, after which groups are randomized (n=8 to 12 mice/group) to once-a-day oral administration (by gavage) for 8 weeks of Seladelpar sodium salt (10 mg/kg in 1% methylcellulose) or vehicle (controls). Animals are housed under 12-hour light/dark cycle and constant temperature of 22°C and receive maximal humane care[4].

References:

- [1]. Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503.
- [2]. Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97.
- [3]. Choi YJ, et al. Effects of the PPAR- δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6.
- [4]. Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674.

Background

Seladelpar sodium salt (MBX-8025) is an orally active, potent and specific PPAR δ agonist with an EC₅₀ of 2 nM, showing more than 750-fold and 2500-fold selectivity over the PPAR α and PPAR γ receptors, respectively. PPAR- δ |2 nM (EC₅₀)

MBX-8025 is an orally active, potent (EC₅₀=2 nM), and specific (750-fold and 2500-fold compared with PPAR α or PPAR γ receptors, respectively) PPAR δ agonist being developed as a lipid-altering agent[2][3].

In atherogenic diet-fed Wt mice, administration of Seladelpar sodium salt reduces body weight by

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

~18% (Pfoz/foz mice. Seladelpar sodium salt lowers serum alanine aminotransferase (ALT) levels in foz/foz mice (PWt mice. Seladelpar sodium salt normalizes serum cholesterol and decreases triglycerides in both genotypes (Pfoz/foz mice ($P < 0.05$)[4].

[1]. Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. *Expert Opin Pharmacother*. 2014 Mar;15(4):493-503. [2]. Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. *J Clin Endocrinol Metab*. 2011 Sep;96(9):2889-97. [3]. Choi YJ, et al. Effects of the PPAR- δ agonist MBX-8025 on atherogenic dyslipidemia. *Atherosclerosis*. 2012 Feb;220(2):470-6. [4]. Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. *Hepatol Commun*. 2017 Jul 31;1(7):663-674.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA